期刊文献+

1-叔丁羰基-4-甲基-3-哌啶酮的合成研究

Synthesis of tert-Butyl-4-Methyl-3-Oxopiperidine-1-Carboxylate
下载PDF
导出
摘要 1-叔丁羰基-4-甲基-3-哌啶酮是合成新型蛋白酪氨酸激酶Jak3抑制剂CP-690550的重要中间体,今以廉价易得的3-羟基-4-甲基吡啶和氯苄为原料,经过SN2取代反应,再经硼氢化还原生成N-苄基-3-羟基-4-甲基哌啶。过程中考察了溶剂对实验的影响,确定最佳溶剂为3.0 mol·L-1 NaOH水溶液,后经Jones氧化,Pd/C催化脱苄及酰基化反应,得到目标产物1-叔丁羰基-4-甲基-3-哌啶酮,总收率达80.2%。该工艺较现有工艺具有反应原料易得,工艺简单,收率高,较易工业化等优点。 tert-Butyl 4-methyl-3-oxopiperidine-1-carboxylate is an important intermediate in the synthesis of the novel protein tyrosine kinase Jak3 inhibitor—CP-690550.In this article,an efficient approach to the synthesis of this interesting compound was proposed.The proposed synthesis process consists of a series of steps: starting from the easy available reagent 4-methylpyridinium,going through the SN2 substitution with benzyl chloride to offer 1-benzyl-3-hydroxy-4-methylpyridium chloride with high yield,and then defining the suitable solvent species and its reasonable concentration for the borohydride reduction with sodium borohydride to provide N-benzyl-3-hydroxy-4-methylpiperidine,consequently,oxidation by Jones reagent under mild temperature to give N-benzyl-3-oxo-4-methylpiperdine,and at last,debenzylation with Pd/C catalyst and acylation to obtain the target product tert-butyl 4-methyl-3-oxopiperidine-1-carboxylate.The total yield can reach 80.2% by using the proposed method.Compared with the existing process,the proposed method has the advantages of easily obtained raw materials,simple in operation and suitable for industrial scale-up.
出处 《高校化学工程学报》 EI CAS CSCD 北大核心 2011年第6期1021-1025,共5页 Journal of Chemical Engineering of Chinese Universities
基金 国家自然科学基金(21076183) 浙江省重点科技创新团队(2009R50002)
关键词 1-叔丁羰基-4-甲基-3-哌啶酮 3-羟基-4-甲基吡啶 SN2取代 硼氢化还原 Jones氧化 tert-butyl 4-methyl-3-oxopiperidine-1-carboxylate 4-methylpyridin-3-ol SN2 substitution Borohydride reduction Jones oxidation
  • 相关文献

参考文献17

  • 1Sohn S J, Forbush K A, Nguyen N, et al. Requirement for Jak3 in mature T cells: its role in regulation of T cell homeostasis [J]. J Immunol, 1998, 160(5): 2130-2138.
  • 2Vincenti E Immunosuppression minimization: current and future trends in transplant immunosuppression [J]. J Am Soc Nephrol, 2003, 14(7): 1940-1948.
  • 3Li X C, Ima A, Li Y, et al. Blocking the conmlongamma-chain of cytokine receptors induces T cell apoptosis and long-term islet alllograft survival [J]. J Immunol, 2000, 164(3): 1193-1199.
  • 4Cacalano N A, Migone T S, Bazan F, et al. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain [J]. EMBO J, 1999, 18(6): 1549-1558.
  • 5Ghorcschi K, Laerencc A, O'Shea J J. Selectivity and therapeutic inhibition of kinascs: to be or not to be? [J]. Nat Immunol, 2009, 10(4): 356-360.
  • 6Ghoreschi K, Laerence A, O'Shea J J. Janus kinases in immune cell signaling [J]. Immunol Rev, 2009, 228(1): 273-287.
  • 7Kobayashi S, Hachiya I, Araki M, et al. Scandium trifluoromethanesulfonate (Sc(OTf)3). A novel reusable catalyst in the Diols-Alder reaction [J]. Tetrahedron Lett, 1993, 34(23): 3755-3758.
  • 8Kobayashi S, Araki M, Ishitani H, et al. Activation of imines by rare earth metal triflates. Ln(OTf)3- or Sc(OTfh-catalyzed reactions of imines with silyl enolates and Diels-Alder reactions of imines [J]. Synlett, 1995(3): 233-234.
  • 9Kobayashi S, Hachiva I, Takahori T, et al. Lanthanide trifluoromethanesulfonates as reusable catalysts. Michael and Diels-Alder reactions [J]. Tetrahedron Lett, 1992, 33(45): 6815-6818.
  • 10Yu L, Chen D, Wang P G. Aqueous aza Diels-Alder reactions catalyzed by lanthanide(III) trifluoromethanesulfonates [J]. Tetrahedron Lett, 1996, 37(13): 2169-2172.

二级参考文献15

  • 1Anna S, Piero D S. Sulindac derivatives for treatment of cancer [P]. WO: 2006134489, 2006-12-21.
  • 2Gardner S H, Hawcrofl G, Hull M A. Effect of nonsteroidal anti-inflammatory drugs on β-catenin protein levels and catenin-related transcription in human colorectal cancer cells [J]. British Journal of Cancer, 2004, 91 (1): 153-163.
  • 3Moon Y, Kim J I, Yang H et al. Growth compensaton/role of sulindac sulfide-induced thrombospondin-1 linked with ERK1/2 and RhoA GTPase signaling pathways [J]. Life Sciences, 2008, 82(11-12): 591-599.
  • 4Pangburn H A, Kraus H, Almen D J et al. Sulindac metabolitos inhibit epidermal growth factor receptor activation and expression [J]. Journal of Carcinogenesis, 2005, 4(1): 16-27.
  • 5Gerhard S, Paul G. Substituted benzylidene indenyl formamides, Acetamides and propionamides [P]. WO: 9747303. 1997-12-18.
  • 6Menander K B, Mayle M J. Method for treating patients with acne by administering substituted sulfonyl indenyi acetic acids, amides and alcohols [P]. USP: 6025394. 2000-02-15.
  • 7Earle K A, Alila H W, Whitehead C Met al. Methods for treatment of cystic fibrosis [P]. USP: 6465494. 2002-10-1 5.
  • 8Earle K A, Alila H W. Methods for treatment of inflammatory bowel disease [P]. USP: 6699894. 2004-03-02.
  • 9Lee J, Lee J, Kim Jet al. N-(3-acyloxy-2-benzylpropyl)-N'-(4-hydroxy-3-methoxybenzyl)thiourea derivatives as potent vanilloid receptor agonists and analgesics [J]. Bioorganie & Medicinal Chemistry, 2001, 9(1): 19-32.
  • 10Musso D L, Cochran F R, Kelley J Let al. Indanylidenes. 1. design and synthesis of (E)-2-(4, 6-difluoro-l-indanylidene)acetamide, a potent, Centrally acting muscle relaxant with antiinflammatory and analgesic activity [J]. Journal of Medicinal Chemistry, 2003, 46(3): 399-408.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部